Chinese Society of Clinical Oncology (CSCO) diagnosis and treatment guidelines for malignant lymphoma 2021 (English version).

Szczegóły

Tytuł:: Chinese Society of Clinical Oncology (CSCO) diagnosis and treatment guidelines for malignant lymphoma 2021 (English version).
Autorzy:: Zhu J; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Lymphoma, Peking University Cancer Hospital & Institute, Beijing 100142, China.
Ma J; Department of Hematology & Oncology, Harbin Institute of Hematology & Oncology, Harbin 150010, China.
Corporate Authors:: Union for China Lymphoma Investigators of Chinese Society of Clinical Oncology
Źródło:: Chinese journal of cancer research = Chung-kuo yen cheng yen chiu [Chin J Cancer Res] 2021 Jun 30; Vol. 33 (3), pp. 289-301.
Typ publikacji:: Journal Article
Język:: English
Imprint Name(s):: Original Publication: Beijing, China : Beijing Institute for Cancer Research, [1988-
References:: Target Oncol. 2019 Apr;14(2):149-158. (PMID: 30904980)
Chin J Cancer Res. 2019 Aug;31(4):557-577. (PMID: 31564800)
J Clin Oncol. 2016 Sep 10;34(26):3150-6. (PMID: 27382100)
Cancer. 1981 Jul 1;48(1):198-206. (PMID: 7237385)
N Engl J Med. 2019 Jun 06;380(23):2225-2236. (PMID: 31166681)
Blood. 2020 Jun 4;135(23):2041-2048. (PMID: 32232482)
Lancet Oncol. 2014 Apr;15(4):424-35. (PMID: 24602760)
Front Oncol. 2021 Feb 19;10:583050. (PMID: 33718104)
J Clin Oncol. 2012 Sep 1;30(25):3093-9. (PMID: 22851556)
Blood. 2017 Oct 12;130(15):1772-1774. (PMID: 28801448)
Chin J Cancer Res. 2019 Oct;31(5):738-739. (PMID: 31814676)
Clin Cancer Res. 2019 Dec 15;25(24):7363-7369. (PMID: 31420358)
Ann Hematol. 2020 Mar;99(3):549-555. (PMID: 31980860)
Blood. 2018 Jul 5;132(1):49-58. (PMID: 29666118)
J Clin Oncol. 2019 Apr 1;37(10):823-833. (PMID: 30785830)
Clin Cancer Res. 2020 Aug 15;26(16):4216-4224. (PMID: 32461234)
Biol Blood Marrow Transplant. 2013 Feb;19(2):173-9. (PMID: 23200705)
Cancer Chemother Pharmacol. 2019 Mar;83(3):443-449. (PMID: 30511217)
Lancet Haematol. 2019 Jun;6(6):e328-e337. (PMID: 31126528)
Leukemia. 2020 Feb;34(2):533-542. (PMID: 31520078)
N Engl J Med. 2019 Aug 1;381(5):432-443. (PMID: 31365801)
Signal Transduct Target Ther. 2020 Dec 30;5(1):289. (PMID: 33376237)
Biol Blood Marrow Transplant. 2008 Dec;14(12):1356-64. (PMID: 19041057)
J Clin Oncol. 2016 Apr 20;34(12):1386-94. (PMID: 26926679)
N Engl J Med. 2018 Sep 6;379(10):934-947. (PMID: 30184451)
J Clin Oncol. 2014 Sep 20;32(27):3059-68. (PMID: 25113753)
Haematologica. 2016 Apr;101(4):474-81. (PMID: 26721893)
Blood. 1975 Aug;46(2):219-34. (PMID: 1139039)
Leukemia. 2021 Jan;35(1):130-142. (PMID: 32152465)
N Engl J Med. 2017 Sep 28;377(13):1250-1260. (PMID: 28953447)
J Hematol Oncol. 2019 Nov 19;12(1):115. (PMID: 31744509)
Lancet. 2011 Jan 1;377(9759):42-51. (PMID: 21176949)
Cancer Med. 2020 Jun;9(11):3765-3774. (PMID: 32281275)
Chin J Cancer Res. 2019 Feb;31(1):162-170. (PMID: 30996574)
Blood. 2016 May 19;127(20):2375-90. (PMID: 26980727)
Ann Oncol. 2013 Dec;24(12):3076-81. (PMID: 24146219)
Cancer. 2006 Apr 1;106(7):1569-80. (PMID: 16502413)
J Clin Oncol. 2017 Jun 10;35(17):1905-1912. (PMID: 28355112)
Blood. 2017 Apr 20;129(16):2224-2232. (PMID: 28167659)
Int J Med Sci. 2018 Jun 4;15(9):867-874. (PMID: 30008598)
Lancet Haematol. 2016 May;3(5):e217-27. (PMID: 27132696)
Lancet Oncol. 2016 Jul;17(7):928-942. (PMID: 27216274)
J Clin Oncol. 2019 Jun 10;37(17):1479-1489. (PMID: 31039052)
J Hematol Oncol. 2019 Mar 4;12(1):22. (PMID: 30832702)
Blood Adv. 2020 Jul 14;4(13):3141-3153. (PMID: 32658985)
Ann Oncol. 2015 Aug;26(8):1766-71. (PMID: 26105599)
Entry Date(s):: Date Created: 20210729 Latest Revision: 20210730
Update Code:: 20240105
PubMed Central ID:: PMC8286890
DOI:: 10.21147/j.issn.1000-9604.2021.03.01
PMID:: 34321826
: Czasopismo naukowe

Informacja